СОВРЕМЕННЫЙ ПОДХОД К РАЗРАБОТКЕ И ИССЛЕДОВАНИЮ БИОАНАЛОГОВ НА ПРИМЕРЕ ПЕРВОГО РОССИЙСКОГО ПРЕПАРАТА МОНОКЛОНАЛЬНЫХ АНТИТЕЛ – АЦЕЛЛБИЯ® (РИТУКСИМАБ)
Published in Research and Practical Medicine Journal • Mar 15, 2015
NobleIDNI0P31W53R26S95
Authors:,,
С М. Алексеев
К. Д. Капланов
Р. А. Иванов
Abstract
Objective. Evaluation of pharmacokinetics, pharmacodynamics, safety and efficacy of rituximab biosimilar (Acellbia, BIOCAD, Russia) used as monotherapy in patients with indolent B-cell non-Hodgkin’s lymphoma in comparison with the parameters of innovator rituximab – MabThera. Materials and methods. ...
Finding related papers...
Discussions
(0)No comments yet
Be the first to share your thoughts!